ArticleCancer research communications2022

Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.

Takao Morinaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.